期刊文献+

PCSK6联合脑钠肽在肾功能不全合并心力衰竭中的应用价值

Application value of PCSK6 combined with BNP in renal insufficiency complicated with heart failure
原文传递
导出
摘要 目的探讨前蛋白转化酶枯草溶菌素6(proprotein converting enzyme subtilysin 6,PCSK6)在慢性肾功能不全(CRI)合并心力衰竭(HF)中的表达水平,PCSK6和脑钠肽(brain natriuretic peptide,BNP)联合诊断在CRI合并HF中的应用价值。方法选取2023年6月1日至2024年1月31日于河南省两家三甲医院肾内科住院的慢性肾功能不全(CRI)患者129例,其中单纯CRI患者53例,HF患者76例。收集患者一般临床资料、BNP、肌酐、尿素氮、尿酸、胱抑素C、肾小球滤过率(eGFR)等检测指标和左心室射血分数、E/A值、室间隔厚度、左心室后壁厚度等心功能参数,采用ELISA方法比较两组血清PCSK6的浓度。采用Spearman相关性分析血清PCSK6与BNP的相关性。ROC曲线分析血清PCSK6和BNP联合诊断对CRI合并HF的预测价值。结果CRI合并HF组PCSK6、BNP等均高于单纯CRI组,且差异有统计学意义(P<0.05)。根据Spearman相关分析结果,血清PCSK6与BNP成正相关(r=0.440,P<0.001)。经ROC曲线分析,血清PCSK6联合BNP诊断CRI合并HF的AUC为0.884,高于PCSK6(AUC=0.822)、BNP(AUC=0.835)。结论血清PCSK6与BNP相关。血清PCSK6联合BNP对于CRI合并HF的诊断具有很好的预测价值,血清PCSK6有望成为CRI合并HF的新型标志物。 Objective To investigate the expression level of proprotein converting enzyme subtilysin 6(PCSK6)in chronic renal insufficiency(CRI)complicated with heart failure(HF),and the value of the combined diagnosis of PCSK6 and brain natriuretic peptide(BNP)in CRI complicated with HF.Methods A total of 129 patients with CRI who were hospitalized in the renal department of two 3A grade hospitals in Henan Province from June 1,2023 to January 31,2024 were selected,including 53 patients with simple CRI and 76 patients with heart failure(HF).General clinical data,BNP,creatinine,urea,uric acid,cystatin C,glomerular filtration rate(eGFR)and other laboratory test indicators,left ventricular ejection fraction,E/A value,ventricular septal thickness,left ventricular posterior wall thickness,and other cardiac function parameters were collected.The serum PCSK6 concentration of the two groups was compared by ELISA.The correlation between serum PCSK6 and BNP was analyzed by Spearman correlation.ROC curve analysis of the diagnosis of serum PCSK6 combined with BNP in the prediction of CRI combined with HF.Results PCSK6 and BNP in HF group with CRI were higher than those in simple CRI group,and the difference was statistically significant(P<0.05).According to Spearman correlation analysis,serum PCSK6 was positively correlated with BNP(r=0.440,P<0.001).According to ROC curve analysis,the AUC of serum PCSK6 combined with BNP in the diagnosis of CRI combined with HF was 0.884,higher than that of PCSK6(AUC=0.822)and BNP(AUC=0.835).Conclusion Serum PCSK6 is related to BNP.Serum PCSK6 combined with BNP has a good predictive value for the diagnosis of CRI combined with HF,and serum PCSK6 is expected to be a new marker of CRI combined with HF.
作者 田文倩 刘诗语 陆静谊 张家明 胡亚会 TIAN Wen-qian;LIU Shi-yu;LU Jing-yi;ZHANG Jia-ming;HU Ya-hui(Department of Clinical Laboratory,Henan Provincial Peoples Hospital,People's Hospital of Zhengzhou University,Peoples Hospital of Henan,Zhengzhou 450003,China;The Fifth Clinical Medical College of Henan University of Chinese Medicine,Zhengzhou 450053,China;Department of Clinical Laboratory,The Fifth Clinical Medical College of Henan University of Chinese Medicine(People's Hospital of Zhengzhou),Zhengzhou 450053,China)
出处 《医药论坛杂志》 2024年第12期1263-1266,1271,共5页 Journal of Medical Forum
基金 河南省自然科学基金青年项目(222300420220) 河南省医学科技攻关计划联合共建项目(LHGJ20210702)。
关键词 肾功能不全 慢性 心力衰竭 PCSK6 脑钠肽 Renal insufficiency,chronic Heart failure PCSK6 Brain natriuretic peptide
  • 相关文献

参考文献10

二级参考文献85

  • 1托伐普坦临床研究协作组,张健,朱文玲.常规治疗基础上联用托伐普坦片治疗心原性水肿的有效性和安全性的多中心随机、双盲、安慰剂对照研究[J].中华心力衰竭和心肌病杂志(中英文),2017,1(1):15-21. 被引量:26
  • 2中国医师协会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会,张宇辉,许顶立,白玲.心力衰竭容量管理中国专家建议[J].中华心力衰竭和心肌病杂志(中英文),2018,2(1):8-16. 被引量:143
  • 3李建平,王晓滨,陈常忠,徐新,冯雁,洪秀梅,龙华,徐希平,霍勇.偶合基本氨基酸裂解酶4基因多态性与高血压的相关性研究[J].中华心血管病杂志,2004,32(9):781-785. 被引量:3
  • 4侯凡凡.慢性肾脏病的心血管并发症[J].中华心血管病杂志,2004,32:16-16.
  • 5何长民 张训 见:何长民 张训主编.前言[A].见:何长民,张训主编.肾脏替代治疗学[C].上海:上海科学技术文献出版社,1999.2..
  • 6Locatelli F, Pozzoni P, Tentori F, et al. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrol Dial Transplant, 2003,18 Suppl 7:2-9.
  • 7Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol, 2002,13:745-753.
  • 8Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol, 2003,41:47-55.
  • 9Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int, 1995,47:186-192.
  • 10Sarnak MJ, Levey AS, Schoolwerth AC,et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation, 2003,108:2154-2169.

共引文献6417

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部